ANTHERA

Pharmaceuticals for the treatment of serious and life-threatening diseases, namely, lupus, lupus with glomerulonephritis, IgA nephropathy, and exocrine pancreatic insufficiency due to cystic fibrosis

Licensing late-stage clinical pharmaceutical products, namely, pharmaceuticals for the treatment of lupus, lupus with glomerulonephritis, IgA nephropathy, and exocrine pancreatic insufficiency due to cystic fibrosis

Developing clinical pharmaceutical products; research and development in the pharmaceutical and biotechnology fields